CTXR Due Diligence Page
5/21/24 Mino-Lok phase 3 achieves primary and secondary endpoints
4/30/24 $15M Offering has 45 Day offering Lockup
3/18/24 Lymphir BLA is Accepted
2/14/24 Q1-24 earnings updates.
Whats next for CTXR....
Lymphir spinoff Q3 2024 -- (updated 5/21/24)
Lymphir BLA resubmission now complete (PDUFA Date Aug. 13 2024)
Halo Lido : Continued engagement with FDA following end of Phase 2b meeting to determine next phase in the development of Halo-Lido for the treatment of hemorrhoids
CTXR February 2024 Coorporate Presentation
0
1-18-24 Bear Creek CTXR Conference Audio
9-12-23 Citius received letter of non compliance for 30 consecutive days under $1.00 min. Bid price
5-18-23 CTXR Added to Russell 2000 and 3000 for 2023
5-17-23 Bear Creek CTXR Conference Audio
Original Mino-Lok calculations based on in patient numbers
Current Links to more Data on CTXR
CTXR Coorporate Presentation Page
All PR Newswire CTXR news related link
TwongStocks Mino-Lok what does 92 events mean and Trial Design
Phase 2 Results showing 74 days MTF and we are looking to beat >38 in P3 (see page 3)
Phase 3 50% of Target news Clip
CTXR Corporate Overview Page Mar 2023
Historical Stock prices by Day
CTXR Charts, Support, Volume, Trends
